Journey Medical Corp Stock Price, News & Analysis

Journey Medical Corporation (Nasdaq: DERM) has announced its inclusion in both the Russell 2000® Index and Russell 3000® Index, effective after market close on June 27, 2025. This milestone is expected to enhance the company's visibility among investors and institutions.

The company's CEO highlighted the successful launch of Emrosi™, their FDA-approved treatment for inflammatory lesions of rosacea in adults. The medication contains 40 mg Minocycline Hydrochloride in a modified-release formulation. Management expressed optimism about 2025 being a transformational year, focusing on expanding access and growing prescription volume for Emrosi™.

Journey Medical Corporation announced new data analysis from Phase 3 trials of Emrosi (DFD-29) for treating moderate-to-severe papulopustular rosacea will be presented at SDPA 2025. The analysis showed Emrosi's efficacy is independent of patient body weight, based on two trials (MVOR-1 and MVOR-2) with 653 total participants. The drug demonstrated superior efficacy compared to both placebo and doxycycline, with success rates up to 75.5% in IGA treatment outcomes. As the lowest FDA-approved oral minocycline dose that doesn't require weight-based adjustments, Emrosi showed significant improvements in inflammatory lesion counts across all weight categories while maintaining a favorable safety profile.

Journey Medical Corporation announced that its FDA-approved rosacea treatment Emrosi was featured on Lifetime TV's 'The Balancing Act'. The segment, which premiered on June 9, 2025, and will be rebroadcast on June 19, showcases Emrosi, a 40 mg Minocycline Hydrochloride Modified-Release Capsule treatment for inflammatory rosacea lesions in adults. The feature included expert insights from Dr. Saurabh Lodha of Pura Dermatology, highlighting Emrosi's unique formulation as the lowest-dose oral minocycline available. The treatment, FDA-approved in November 2024, is available by prescription at specialty pharmacies and represents what the company believes could be a paradigm shift in rosacea treatment.

Journey Medical Corporation (NASDAQ: DERM) reported its Q1 2025 financial results, highlighting total net product revenues of $13.1 million, consistent with $13.0 million in Q1 2024. The company successfully launched Emrosi™, their new oral rosacea treatment, contributing $2.1 million in incremental revenue. The company's gross margin improved to 64% from 54% year-over-year.

Key financial metrics include a reduced net loss of $4.1 million ($0.18 per share) compared to $10.4 million ($0.53 per share) in Q1 2024. Cash position strengthened to $21.1 million as of March 31, 2025. The company reported no R&D costs in Q1 2025, down from $7.9 million in Q1 2024, while SG&A expenses increased by $2.1 million due to Emrosi launch activities.

Notable achievements include the publication of Emrosi's Phase 3 trial results in JAMA Dermatology, showing superiority over Oracea® and placebo, and its inclusion in the National Rosacea Society's Treatment Algorithms.

Journey Medical Corporation (NASDAQ: DERM), a commercial-stage pharmaceutical company focused on marketing FDA-approved dermatological treatments, has scheduled its first quarter 2025 financial results announcement for May 14, 2025, after U.S. market close.

The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day. U.S. participants can dial 1-866-777-2509, while international callers should use 1-412-317-5413. The webcast will be accessible through Journey Medical's website and will remain available for approximately 30 days after the call.

Journey Medical (NASDAQ: DERM) has promoted Ramsey Alloush from General Counsel to Chief Operating Officer (COO), while maintaining his General Counsel position. Alloush, who joined the company in 2020, brings over 15 years of pharmaceutical industry experience.

During his tenure at Journey Medical, Alloush has played a important role in navigating regulatory landscapes, managing financing transactions including the company's 2021 IPO, and overseeing acquisitions and licensing. His background includes experience at the Securities and Exchange Commission and Medicis Pharmaceuticals' Aesthetics Division.

The appointment comes at a strategic time as Journey Medical prepares for the launch of Emrosi™, a new dermatological treatment. The company focuses on marketing FDA-approved prescription pharmaceutical products for dermatological conditions.

Journey Medical (DERM) reported its full-year 2024 financial results, with total revenues of $56.1 million, meeting all financial guidance targets. The company received FDA approval for Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for rosacea treatment in November 2024, with initial distribution and first prescriptions already underway.

Key financial metrics include:

• Product revenue decreased 8% to $55.1 million from $59.7 million in 2023
• Net loss of $(14.7) million, or $(0.72) per share, compared to $(3.9) million in 2023
• Adjusted EBITDA of $0.8 million
• Cash position of $20.3 million as of December 31, 2024

The company's Phase 3 clinical trial results for Emrosi were published in JAMA Dermatology, demonstrating successful achievement of co-primary and secondary endpoints. Full promotion is expected to begin in April 2025.

Journey Medical (NASDAQ: DERM) has announced the launch and first prescriptions of Emrosi™, a 40 mg Minocycline Hydrochloride Modified-Release Capsule treatment for inflammatory lesions of rosacea in adults. The medication, which received FDA approval in November 2024, is now available through specialty pharmacy chains.

Emrosi is the lowest-dose oral minocycline available, featuring a unique 10 mg immediate release and 30 mg extended release formulation. Clinical trials demonstrated superior efficacy compared to Oracea® and placebo while maintaining a comparable safety profile. The most common adverse reaction reported was dyspepsia, occurring in ≥1% of subjects.

Journey Medical (Nasdaq: DERM) has scheduled the release of its year end 2024 financial results on Wednesday, March 26, 2025, after U.S. financial markets close. The commercial-stage pharmaceutical company, which specializes in marketing FDA-approved prescription pharmaceutical products for dermatological conditions, will host a conference call and audio webcast at 4:30 p.m. ET on the same day.

Interested U.S. participants can dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international) to join the conference call. Registration is available at https://dpregister.com/sreg/10197674/feaf5b7354. A live audio webcast will be accessible on the company's website and remain available for approximately 30 days after the call.